UNITY Biotechnology to Participate in Fireside Chat at the Goldman Sachs 41st Annual Global Healthcare Conference
UNITY Biotechnology announced its participation in the Goldman Sachs 41st Annual Global Healthcare Conference on June 11, 2020, at 4:40 PM E.T.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
UNITY Biotechnology announced its participation in the Goldman Sachs 41st Annual Global Healthcare Conference on June 11, 2020, at 4:40 PM E.T. The event will be held virtually, and a live audio webcast will be available on the company's website, with an archived replay available for 90 days. UNITY focuses on developing therapeutics to extend healthspan by targeting cellular senescence, which contributes to age-related diseases. The company's senolytic medicines aim to eliminate senescent cells, potentially reversing conditions like osteoarthritis and age-related eye diseases.
Details
News Market Reaction – UBX
The recorded move for UBX in the trading session of this news was -2.03%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, June 11, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that members of its senior management team will participate in the Goldman Sachs 41st Annual Global Healthcare Conference.
Goldman Sachs 41st Annual Global Healthcare Conference
Date: June 11, 2020
Fireside Chat Time: 4:40 PM E.T. (updated)
Location: Virtual
A live audio webcast of the fireside chat will be available through the Investors & Media section of UNITY’s website. An archived replay will be available for 90 days following the event.
About UNITY
UNITY is developing therapeutics to extend healthspan with an initial focus on cellular senescence. UNITY believes that the accumulation of senescent cells is a fundamental mechanism of aging and a driver of many common age-related diseases. Cellular senescence is a natural biological state in which a cell permanently halts division. As senescent cells accumulate with age, they begin secreting inflammatory factors, proteases, fibrotic factors, and growth factors, that disturb the tissue micro-environment. This collection of secreted proteins is referred to as the Senescence Associated Secretory Phenotype, or SASP. UNITY is developing senolytic medicines to eliminate senescent cells and thereby stop the production of the SASP, which UNITY believes addresses a root cause of age-related diseases. By stopping the production of the SASP at it source, UNITY believes senolytic medicines could slow, halt, or reverse diseases such as osteoarthritis and age-related eye diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter.
Investors
Endurance Advisors
Mike Zanoni
mzanoni@enduranceadvisors.com
Media
Canale Communications
Jason Spark
jason@canalecomm.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.